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Abstract
Carbon monoxide (CO) is a pollutant commonly recognized for its
toxicological attributes, including CNS and cardiovascular effects.
But CO is also formed endogenously in mammalian tissues. Endog-
enously formed CO normally arises from heme degradation in a
reaction catalyzed by heme oxygenase. While inhibitors of endoge-
nous CO production can raise arterial pressure, heme loading can
enhance CO production and lead to vasodepression. Both central and
peripheral tissues possess heme oxygenases and generate CO from
heme, but the inability of heme substrate to cross the blood brain
barrier suggests the CNS heme-heme oxygenase-CO system may be
independent of the periphery. In the CNS, CO apparently acts in the
nucleus tractus solitarii (NTS) promoting changes in glutamatergic
neurotransmission and lowering blood pressure. At the periphery, the
heme-heme oxygenase-CO system can affect cardiovascular functions
in a two-fold manner; specifically: 1) heme-derived CO generated
within vascular smooth muscle (VSM) can promote vasodilation, but
2) its actions on the endothelium apparently can promote vasocon-
striction. Thus, it seems reasonable that the CNS-, VSM- and endothe-
lial-dependent actions of the heme-heme oxygenase-CO system may
all affect cardiac output and vascular resistance, and subsequently
blood pressure.
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Changing personalities
Carbon monoxide is readily recognized
for its toxic effects. Its colorless and odorless
properties, combined with its tenacious abil-
ity to compete with oxygen for binding to
hemoglobin, can lull its victims into a gradual
unnoticed somnolence and vasodepression
which all too often are fatal. Less appreci-
ated is the tendency for long periods of low
level carbon monoxide exposure to promote
neural pathologies and elicit changes in car-
diovascular functions (1,2).
Carbon monoxide binds to hemoglobin
and a minimum of 0.5-1% carboxyhemoglo-
bin is inevitably detected in most mamma-
lian species. While initially thought to be a
manifestation of widespread environmental
contamination, it was eventually realized that
these persistent carboxyhemoglobin levels
arise from carbon monoxide which is formed
within the host. This endogenously formed
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carbon monoxide arises primarily as a prod-
uct of heme metabolism (3). Until recently,
endogenously formed carbon monoxide was
regarded simply as a waste product, but there
is now a growing awareness that even en-
dogenously formed carbon monoxide may
influence biological functions (4).
While much has been learned about the
toxicological actions of carbon monoxide
and about the biochemistry related to endog-
enous carbon monoxide formation, only re-
cent studies have tried to functionally link
these two areas. The purpose of this review
is to highlight some of the important physi-
cal properties and the biochemical actions of
carbon monoxide, to review some of the
tools used to investigate the endogenous car-
bon monoxide system, and to summarize the
apparent acute effects of this system as they
relate to cardiovascular functions.
The toxicological aspects of carbon mon-
oxide have been studied for decades. Di-
verse models of distribution kinetics, the
performance of dose-time related actions,
and the identification of multiple organ in-
volvement are evidence that the actions of
carbon monoxide can be quite complex (5).
While the critical details of the toxicological
actions of carbon monoxide are admittedly
well beyond the scope of the current review,
comprehensive works on the biochemical
and cardiovascular effects of carbon monox-
ide intoxication have been published else-
where (1,2,5,6). Since the toxicology litera-
ture serves as a basis for many of the known
actions of carbon monoxide, a few features
culled from those studies should still be
mentioned to appreciate some of the poten-
tial actions of endogenously formed carbon
monoxide on biological processes.
Messenger systems
Heme proteins are often identified by
their tendency to bind carbon monoxide (7).
For heme proteins possessing enzymatic
properties, the binding of carbon monoxide
is often accompanied by changes in their
metabolic activities (7-10). Accordingly, any
or all heme proteins would seem particularly
well suited to be potentially involved in the
biological actions of carbon monoxide.
Soluble guanylate cyclase is a commonly
considered candidate (4,8). Carbon monox-
ide activates purified soluble guanylate cy-
clase to increase cGMP formation approxi-
mately two-fold, which is relatively modest
when compared to the 100-fold greater in-
creases that may be obtained by activation
with nitric oxide (8). However, such differ-
ences in efficacy do not preclude the possi-
bility that functional effects may still arise
from the increases in cGMP production which
can be attained from carbon monoxide-in-
duced activation of soluble guanylate cy-
clase.
Carbon monoxide was shown to dilate
vascular smooth muscle preparations in a
manner which was prevented by methylene
blue, an inhibitor of soluble guanylate cy-
clase (11). Consequently, it was suggested
that carbon monoxide-induced vasodilation
of vascular smooth muscle was soluble guan-
ylate cyclase-dependent. But recent studies
employing newly developed inhibitors of
soluble guanylate cyclase have shown that
carbon monoxide-induced dilation may pro-
ceed even when soluble guanylate cyclase
activity has been blocked (12,13). These
findings suggest that carbon monoxide, at
least under some conditions, may promote
relaxation of vascular smooth muscle by
processes which are soluble guanylate cy-
clase-independent.
The cytochrome P-450 family of enzymes
(cytP450), which collectively display a spec-
tral shift in response to carbon monoxide
binding, are another class of enzymes pro-
posed as potential mediators of carbon mon-
oxide-induced effects (7). However, it has
been suggested that the CO/O2 ratio required
to produce significant binding to most types
of cytP450 enzymes would also be likely to
overwhelm the O2-carrying capacity of cir-
3Braz J Med Biol Res 32(1) 1999
Carbon monoxide and cardiovascular control
culating hemoglobin to a fatal extent (2,5).
In contrast to other P450 enzymes, the
activities of some mitochondrial cytochrome
oxidases may be affected by levels of carbon
monoxide which fall short of producing fatal
hypoxia (5). Also, the binding of carbon
monoxide to these cytochrome oxidases is
apparently further enhanced during increased
metabolic demand and in environments of
reduced oxygen tensions. As these cyto-
chromes of the mitochondrial membrane are
involved in electron transport and in the
generation of ATP, disruption of the associ-
ated electron shuttling may in turn lead to
multiple functional effects by interfering with
kinase- and other ATP-dependent processes.
Prostaglandin G/H synthase (14), cata-
lases (15), and potassium channels (16) are
also amongst the suggested potential targets
for the actions of carbon monoxide. In addi-
tion, cyclooxygenase-2 has recently been
recognized to be heme-bearing (17), and
thus may also participate in the biological
actions of carbon monoxide. The relative
contributions of each of these systems to the
biological effects of carbon monoxide, if
any, have yet to be fully understood.
Endogenous sources of carbon
monoxide and their regulation
Endogenously formed carbon monoxide
arises primarily from the degradation of
monomeric free heme and is generated in a
reaction catalyzed by the heme oxygenases.
During this reaction heme is degraded to
release equimolar quantities of iron, biliver-
din and carbon monoxide (3). The iron is
primarily recycled into the formation of new
heme while the biliverdin is rapidly con-
verted to bilirubin by an abundance of biliver-
din reductases (18). The carbon monoxide
product eventually binds to circulating he-
moglobin and is then transported as car-
boxyhemoglobin until it is excreted through
ventilation. Heme oxygenase activity in some
tissue homogenates is sufficient to generate
2 nmol of carbon monoxide/mg protein per
hour (19). Given that 1% carboxyhemoglo-
bin levels in the blood are quite common,
this constitutes a minimum load of approxi-
mately 100 µmol/l carbon monoxide trapped
within the vascular space.
Normally, endogenously formed carbon
monoxide arises almost exclusively from the
metabolism of heme by heme oxygenase. At
least three isoforms of heme oxygenase have
been identified (3,20) which originate from
multiple mRNAs (21,22). Some heavy met-
als, metalloporphyrins, as well as heme, have
been shown to chronically induce heme oxy-
genase-1 while having relatively little effect
on the expression of heme oxygenase-2 (21).
Very little is known about the recently dis-
covered heme oxygenase-3 isoform (20). The
regulation of heme oxygenase expression is
quite complex (21), but it is clear that the
induction of heme oxygenase in some tis-
sues may allow them to participate in the
local generation of carbon monoxide where
they otherwise might be limited by a defi-
ciency of the mediating enzyme.
Increased expression of heme oxygenase
protein is not the only means for stimulating
the generation of carbon monoxide and other
heme oxygenase products. Alternatively,
heme loading can rapidly increase plasma
bilirubin (23) in a manner which precedes
discernable induction of the enzyme. Since
the provision of the substrate rapidly in-
creases the generation of heme oxygenase
products, it is clear that heme availability
can be a rate-limiting step for the endoge-
nous production of carbon monoxide.
Biochemical evidence derived from stud-
ies of delta aminolevulinic acid (dALA) syn-
thase and its feedback inhibition by heme
(24) imply that normal resting levels of free
heme may be in the vicinity of 0.5-1.0 µmol/
l. Oddly, heme loading in 50-fold excess of
these levels typically increases plasma bi-
lirubin levels and CO production by only 2-
3-fold (23). The reason for these divergent
trends may be related to the physical proper-
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ties of heme. In aqueous solutions at physi-
ological pH, monomeric free heme has been
characterized as reaching saturation at around
2 µmol/l (25). Heme which is loaded beyond
this limit progressively forms dimeric struc-
tures and polymeric chains (25). While these
dimeric/polymeric forms may potentially
constitute heme stores, they apparently do
not function as substrates for heme oxyge-
nase (3,26). Consequently, it can make sense
that heme loading might only double or triple
the concentration of monomeric free heme
in tissues. In turn, this increase in heme
oxygenase substrate availability should be
paralleled by increases in carbon monoxide/
bilirubin formation (23).
Endogenously formed carbon monoxide
does not arise solely from the degradation of
heme. In fact, inhibition of heme oxygenase
activity reduces carbon monoxide produc-
tion by only 30-50% at best (27). While
heme degradation is usually the primary
source of endogenously formed carbon mon-
oxide, the blockade of heme oxygenase ac-
tivity initiates the generation of carbon mon-
oxide from alternative sources including a
process involved in fatty acid metabolism
(27,28). The mechanisms underlying these
shifts in carbon monoxide sources are poorly
understood.
The suggestion that endogenously formed
carbon monoxide might participate in bio-
logical functions was highlighted in a semi-
nal work by Gerald Marks (4). Noting that
carbon monoxide is an activator of soluble
guanylate cyclase, and that carbon monox-
ide is endogenously formed as part of heme
metabolism, Marks proposed that heme-de-
rived carbon monoxide might function in a
manner synonymous to that of nitric oxide.
Indeed both systems produce low molecular
weight gasses which are activators of soluble
guanylate cyclase, and the catalytic forma-
tion of both gases are NADPH-dependent
(3,29).
But the nitric oxide- and carbon monox-
ide-generating systems also exhibit some very
important differences. Nitric oxide is highly
labile, exhibiting a biological half-life of
seconds (29), whereas carbon monoxide is
unusually stable and highly resistant to trans-
formation (1,2). As mentioned earlier, nitric
oxide is a powerful activator of soluble guan-
ylate cyclase, whereas carbon monoxide is a
weak activator of this cGMP-generating en-
zyme (8). Under most conditions the consti-
tutive forms of nitric oxide synthase are
primarily found in neurons and endothelium
(29) but are relatively absent from vascular
smooth muscle. While the constitutive
isoform of heme oxygenase is similarly preva-
lent in neuronal and endothelial tissue do-
mains (30), it differs from its nitric oxide-
generating counterpart by being abundant
within the vascular smooth muscle. Since
heme oxygenase is abundant in the smooth
muscle domain of most blood vessels, con-
ditions which promote endothelial damage
or dysfunction may potentially disrupt some
aspects of the nitric oxide-generating system
while leaving the heme-derived carbon mon-
oxide-generating system intact.
Studying the heme-heme oxygenase-
carbon monoxide system: tools and
approaches
Chronic heme oxygenase induction
Induction of heme oxygenase-1 protein
is often accompanied by an array of heat
shock stress-related proteins and functional
derangements (21,30). Heavy metal salts and
other stress-related events are often used to
induce expression of heme oxygenase-1 pro-
tein and promote heme oxygenase activity
(30,31). While such chronic inductions may
reflect potential pathological states which
could lead to persistent elevations in endog-
enous carbon monoxide production, this tech-
nique may be less than optimal to distinguish
the actions of heme oxygenase-derived car-
bon monoxide from those of the other simul-
taneously expressed heat-shock proteins.
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Acute manipulations of the heme-heme
oxygenase-carbon monoxide system
Studies which focus on the functional
effects of endogenously formed carbon mon-
oxide may alternatively be approached by
increasing and decreasing tissue levels of
acutely endogenously formed carbon mon-
oxide. Unfortunately, no selective chelators
or metabolizing agents are currently avail-
able to inactivate carbon monoxide once it
has been formed. But the formation of heme-
derived carbon monoxide can be increased
by providing heme oxygenase substrate
(3,23,26) or conversely decreased by using
metalloporphyrins that compete with heme
for binding to the heme oxygenase enzyme
(13,19,21,23,24,27). Such a strategy has been
used to identify heme-induced effects which
arise from formation of a heme oxygenase
product (19,23). Specifically, heme-induced
effects which can be prevented and/or re-
versed by an inhibitor of heme oxygenase
are likely to be consequent to the formation
of a heme oxygenase product. As iron, biliver-
din and carbon monoxide are the metabolic
products of heme oxygenase-mediated me-
tabolism of heme (3,21), the actions of these
three products may in some cases be com-
pared to identify the specific product which
is most likely to account for the heme oxyge-
nase-induced response.
The use of heme to drive heme oxyge-
nase activity in experimental settings is com-
plicated by its tendency to aggregate in aque-
ous solutions at physiological pH (25,32)
and to degrade during storage (32). An acetic
environment may in some cases be used to
increase porphyrin solubility, but such con-
ditions may also damage porphyrin integrity
(25). Alternatively, bases such as Tris and
sodium hydroxide have been used to in-
crease the solubility of porphyrins, but these
caustic solvents may also promote substan-
tial tissue damage. Some porphyrins are
soluble in ethanol, but ethanol can alter por-
phyrin metabolism by driving the synthesis
of dALA (24), the rate-limiting step in the
formation of new heme. While disodium
carbonate has been used to solubilize hema-
tin for clinical applications (24), the result-
ing preparation is still susceptible to degra-
dation during storage (32).
The solubility limitations associated with
heme can easily be overcome by dissolving
it in an amino acid solution. Heme-L-arginate
is one such commercially available prepara-
tion (32,33) which is used in the treatment of
porphyrin metabolic disorders (24). This
preparation boosts the solubility of heme to
38 mmol/l, maximizes monomeric heme
availability, and yields a preparation which
can be stored for months without discernible
degradation (32). For some experimental
protocols, heme-L-arginate may create meth-
odological problems, since L-arginine is a
substrate for nitric oxide synthase-mediated
formation of nitric oxide (29). Alternatively,
an arginine-free preparation of heme-L-
lysinate can be made by replacing L-arginine
with L-lysine (32). Since heme-L-arginate
and heme-L-lysinate each demonstrate heme
oxygenase substrate activities identical to
that of hematin (32), these preparations seem
particularly well suited as sources of heme
for experimental purposes.
Metalloporphyrins may be used to inhibit
endogenous formation of carbon monoxide.
These pharmacological tools resemble heme
in their porphyrin structure, but the iron core
is substituted by a heavy metal such as Zn,
Sn, Cr, Co or Cu (19,21,27,30,34). The ten-
dency for some of these substituted porphy-
rins to compete with heme for binding to the
heme oxygenase enzyme has led to their use
as heme oxygenase inhibitors. Accordingly,
such inhibitors can also be used to inhibit the
formation of heme-derived carbon monox-
ide (27).
Photolability is a serious problem with
some metalloporphyrins. Some metallopor-
phyrins, most notably those which are tin-
bearing, can undergo non-enzymatic degra-
dation to release carbon monoxide when
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they are exposed to light (35). Concerns
have also been raised over the potential in-
teractions of metalloporphyrins with soluble
guanylate cyclase (36,37). It is abundantly
clear that the substituted metalloporphyrins
do not participate in the activation of soluble
guanylate cyclase in a manner similar to
heme (36), but demonstrations that these
substituted metalloporphyrins produce func-
tional effects which arise from their direct
action on soluble guanylate cyclase have not
been forthcoming.
Carbon monoxide is an obvious tool used
to confirm that a heme-induced effect may
be attributed to the endogenously formed
carbon monoxide product. An array of tech-
niques for preparing and administering car-
bon monoxide have been explored (1). For
in vitro studies, carbon monoxide is water
soluble and thus can be easily prepared in
physiological buffer solutions. In contrast,
administration of carbon monoxide for in
vivo studies can be substantially compli-
cated by its distribution kinetics which are
markedly influenced by the affinity of this
gas for heme proteins (1,2). Carbon monox-
ide has been administered through inhala-
tion (1), but the delivery of carbon monoxide
to the tissues by this method is reliant on its
delivery as carboxyhemoglobin. This means
that carbon monoxide must bind to hemo-
globin before it can be delivered to the tis-
sues. In turn, this event produces hypoxia
that must precede appreciable accumulations
of carbon monoxide in the tissues. Intrave-
nous administration of carbon monoxide
solutions is equally disadvantageous because
of this complication.
The intraperitoneal administration of car-
bon monoxide may offer some advantages.
Using this simple and efficient technique,
marked changes in cardiovascular function
can precede dramatic changes in carboxyhe-
moglobin levels (38). When carbon monox-
ide gas is injected into the peritoneum, its
appearance in the vasculature as carboxyhe-
moglobin is not immediate and in some spe-
cies may not plateau for hours (2). The de-
layed transit of this water soluble and low
molecular weight gas from the peritoneum to
the vascular space strongly suggests that the
extravascular tissues also possess a marked
affinity for carbon monoxide. Furthermore,
it supports what toxicologists have empha-
sized for years, that carboxyhemoglobin lev-
els are of limited value when judging the
carbon monoxide content of the extravascu-
lar space (1,2).
The heme-heme oxygenase-carbon
monoxide system and cardiovascular
functions
Since blood pressure is calculated as the
product of cardiac output and total peripher-
al resistance, cardiovascular functional stud-
ies accordingly focus on these determinants.
Based upon the toxicological literature and
the logical rationale proposed by Gerald
Marks (2,4,8), it appears that heme-derived
carbon monoxide might serve as a vasodila-
tor and accordingly tend to be vasodepressive.
Chronic blood pressure effects of the heme-
heme oxygenase-carbon monoxide system
Volumes have been published on various
aspects of heme oxygenase induction (21,30).
Studies preceding the overt suggestion that
endogenous carbon monoxide may partici-
pate in biological functions showed that in-
ducers of heme oxygenase such as SnCl2
could chronically slow the development of
hypertension in spontaneously hypertensive
rats (SHR) (31). Since the vasodepressive
effects were accompanied by decreases in
microsomal cytochrome content, those early
studies attributed the blood pressure lower-
ing effects of heme oxygenase induction to a
state of heme depletion and a consequent
reduction of the formation of cytP450-de-
rived vasoconstrictive eicosanoids (31).
While this explanation was consistent with
the findings, those corollary studies did not
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directly verify a state of free heme depletion.
It was then also shown that chronic heme
loading could induce heme oxygenase and
similarly slow down the development of hy-
pertension in SHRs (39). Since monomeric
free heme is the substrate for heme oxyge-
nase, and since heme loading is known to
increase bilirubin production, this suggests
that heme substrate availability is not im-
paired by these treatments. Rather, it sup-
ports the idea that a heme oxygenase product
such as carbon monoxide may be involved in
the vasodepressive effect.
Certainly such evidence does not preclude
a role for cytP450-derived eicosanoids in heme
oxygenase-induced vasodepression. Indeed,
changes in cytP450 and heme oxygenase con-
tent accompany a variety of chronic disease
states (21,30,31). Nonetheless, studies which
rely solely on chronic corollaries between in-
duction and functions are not able to distin-
guish the effects of heme oxygenase activity
from those of the other simultaneously ex-
pressed heat-shock proteins. Interpretations of
studies using chronic treatment of heme oxy-
genase inhibitors are similarly complicated as
such inhibitors tend to induce heme oxyge-
nase along with other heat-shock proteins
(21,31), while at the same time directly inhib-
iting heme oxygenase. In addition, these chronic
treatments may potentially produce effects by
altering other less investigated functional as-
pects of porphyrin metabolism-dependent pro-
cesses such as dALA synthase activity or glu-
tathione metabolism (24). Furthermore, chronic
inhibition of heme oxygenase activity through
the use of metalloporphyrins or even highly
specific antibodies may have limited influence
on total carbon monoxide production as sources
of nonheme-derived carbon monoxide may be
greatly amplified during such conditions (27).
Acute blood pressure effects of the heme-
heme oxygenase-carbon monoxide system
The use of heme oxygenase substrates
and inhibitors to acutely manipulate heme
oxygenase activity constitutes a major de-
velopment for studying the biological ac-
tions of the heme-heme oxygenase-carbon
monoxide system. This strategy optimizes
the ability to examine heme oxygenase-re-
lated effects in a setting which maximally
precedes potential enzyme induction and
shifting in carbon monoxide sources. By so
doing, these inhibitors of heme oxygenase
may also be used to evaluate the contribu-
tions of the heme-heme oxygenase-carbon
monoxide system to basal functions.
Systemic administration of metallopor-
phyrins which inhibit heme oxygenase can
rapidly produce vasoconstriction and raise
blood pressure in rats (40). This suggests
that a heme oxygenase product serves to
reduce vascular tone. In contrast, heme prepa-
rations that drive heme oxygenase-mediated
formation of carbon monoxide, such as heme-
L-lysinate, lower blood pressure in chroni-
cally hypertensive SHR and DOCA-salt rat
models and in rats made acutely hyperten-
sive by phenylephrine infusion (23). These
heme-induced decreases in blood pressure
can be prevented by pretreatment with in-
hibitors of heme oxygenase. This suggests
that the vasodepressive actions of heme are
consequent to the formation of a heme oxy-
genase product.
It is well established that the heme oxy-
genase-mediated degradation of heme forms
three products: iron, biliverdin and carbon
monoxide (3). Iron chelation does not pre-
vent heme-induced vasodepression in SHRs
(23), and biliverdin does not acutely pro-
mote vasodepression in either normotensive
or hypertensive models (23,40). However,
intraperitoneal injection of carbon monox-
ide does preferentially lower blood pressure
in hypertensive models (23). Thus, it ap-
pears that the heme-induced vasodepression
is more likely to arise from the formation of
the carbon monoxide product.
Hypertensive models do seem to display
an enhanced sensitivity for heme-induced
vasodepression (23). While this might sug-
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gest that the hypertensive models such as the
SHRs are heme-, heme oxygenase-, or car-
bon monoxide-deficient compared to nor-
motensive Sprague-Dawleys, these two
strains do not differ in plasma bilirubin con-
tent (23). Furthermore, matched loadings
with heme preferentially lower blood pres-
sure in the hypertensive models despite simi-
lar 2-3-fold elevations in the plasma biliru-
bin content in both normotensive and hyper-
tensive strains. A variety of hypertensive
models have been found to be both acutely
(23) and chronically (1) more sensitive to the
vasodepressive actions of exogenously ap-
plied carbon monoxide than their normoten-
sive counterparts. These tendencies indicate
that these normotensive and hypertensive
models do not appear to differ in their abili-
ties to generate heme oxygenase products,
including carbon monoxide. Rather they sug-
gest that SHRs, and perhaps other hyperten-
sive models as well, may be more sensitive
to the vasodepressant actions of the carbon
monoxide product.
CNS involvement in heme oxygenase-related
cardiovascular effects
Heme oxygenase and its activity have
been identified in the brain (21,40-42), but
its distribution is such that it forms distinct
tracts (41). While some metalloporphyrins
like ZnDPBG have been designed to pass the
blood brain barrier to inhibit heme oxyge-
nase activity in the brain (27,40), studies
using radiolabeled tags show that heme does
not pass the blood brain barrier (33). In
addition, dALA synthase, the rate-limiting
enzyme in the formation of new heme, and
the other enzymes involved in heme synthe-
sis have been identified in brain tissues (24).
The finding that the brain is insulated from
infiltration by circulating heme but locally
possesses the metabolic processes for heme
synthesis suggests that the CNS may consti-
tute a heme oxygenase functional unit which
is distinct from that of peripheral tissues.
Intraperitoneal administration of ZnDPBG
can inhibit heme oxygenase activity both at
the periphery and in the brain, decrease the
systemic production of carbon monoxide
(27), and increase the blood pressure of the
awake rat in a manner which is paralleled by
an increase in total peripheral resistance (40).
This pressor response can be prevented by
alpha-1-adrenergic receptor antagonists or
pharmacological blockade of ganglionic
function, but not by bilateral sino-aortic deaf-
ferentation. These findings suggest that
ZnDPBG-induced elevations in blood pres-
sure may involve a heme oxygenase-related
action which is central (40,43).
The nucleus tractus solitarius (NTS) is
the site of termination of cardiovascular and
respiratory afferent fibers in the medulla
oblongata (44) and is a key structure in glu-
tamatergic-mediated cardiovascular afferents
and an integrative region of baroreceptor
and chemoreceptor responses (45). Systemic
inhibition of heme oxygenase has been shown
to attenuate the pressure-bradycardia rela-
tionship, which is modulated via the NTS
(43). Inhibitors of heme oxygenase can af-
fect glutamatergic-mediated depolarization
in isolated NTS preparations (46). Since iso-
lated NTS tissues respond to manipulations
of the heme-heme oxygenase-carbon mon-
oxide system, and since the NTS is involved
both in the modulation of baroreceptor re-
flex activity and in the establishment of blood
pressure, it seems that the NTS might be
involved in the ZnDPBG-induced pressor
response.
This notion is supported by the observa-
tion that microinjections of ZnDPBG into
the NTS are able to increase blood pressure
in a manner that can be reversed by microin-
jections of carbon monoxide (43). Likewise,
microinjections of carbon monoxide into the
NTS can reverse the elevation in blood pres-
sure produced by systemic administration of
ZnDPBG (43). Thus it appears that the heme
oxygenase product formed in the NTS exerts
a vasodepressive influence; it also appears
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that the heme oxygenase product is likely to
be carbon monoxide.
L-Glutamate is a neurotransmitter in-
volved in NTS-mediated afferent barorecep-
tor activity. NTS microinjections of heme
oxygenase inhibitors do attenuate the pres-
sor responses to microinjections of L-gluta-
mate (47) and interfere with baroreceptor
activity. Such findings suggest that heme
metabolism may locally interact with gluta-
matergic transmission in the NTS. Even so,
it remains unclear if these glutamatergic-
linked effects arise solely from its influences
on carbon monoxide product formation.
While evidence is mounting to suggest
neuromodulatory roles for heme oxygenase-
derived carbon monoxide, special caution
should be observed when designing and in-
terpreting CNS studies using metalloporphy-
rins. The potential of metalloporphyrin and
heme to affect the CNS independently of
carbon monoxide generation may represent
a highly complicated topic. In the porphyrin
metabolic pathway, the formation of dALA
is enzymatically mediated and constitutes
the rate-limiting step in the formation of new
heme (24). In turn, the concentration of free
heme serves as a feedback inhibitor of dALA
synthase activity. This is the mechanism by
which tissue levels of heme are effectively
maintained. This heme precursor, dALA, is
structurally related to gamma aminobutyric
acid (GABA). In addition, heme itself dem-
onstrates affinity for benzodiazepine recep-
tors. It is accepted that GABA and benzodi-
azepine receptor functions are cooperative
and may play important roles in central regu-
lation of blood pressure. While the effects of
dALA on GABA receptors and the effects of
heme on benzodiazepine receptor functions
have not been fully characterized, it should
be mentioned that any maneuver which in-
fluences heme availability may also poten-
tially affect benzodiazepine- and GABA-
related functions in the CNS.
Acute intact animal studies which use
systemic administration of heme are likely to
be less complicated by CNS-related effects
since heme does not cross the blood brain
barrier (33). However, inhibitors of heme
oxygenase which cross the blood brain bar-
rier (40), and carbon monoxide as well (1,2),
can potentially affect the blood pressure by
acting directly on the NTS or other central
structures. Since the CNS exerts a powerful
influence on cardiovascular functions, the
actions of the heme-heme oxygenase-carbon
monoxide system directly on vascular activ-
ity may be best addressed by using isolated
vessel preparations which are devoid of cen-
tral and circulating influences.
Endogenous carbon monoxide and
vascular tone: dual actions
Carbon monoxide as a vasoconstrictor
Heme oxygenase has been identified both
in arteriolar and venular smooth muscle, and
has also been located in arteriolar endotheli-
um (48). The findings that carbon monoxide
can stimulate soluble guanylate cyclase (8)
and relax preparations of vascular smooth
muscle (11) have prompted suggestions that
carbon monoxide may lower blood pressure
by promoting vasodilation (4). In contrast,
earlier studies (7,49-52) have provided ample
evidence that carbon monoxide can bind to
nitric oxide synthase and inhibit the produc-
tion of nitric oxide, a vasodilator. If so, it
might be expected that carbon monoxide
could block basal nitric oxide production
and cause vasoconstriction with a conse-
quent increase in blood pressure. While these
two functionally opposing roles of endog-
enously formed carbon monoxide in vascu-
lar tone are equally plausible, several studies
using isolated vessels and perfused prepara-
tions (7,53-56) have suggested that heme-
derived carbon monoxide may be vasodila-
tory. Such reports have understandably typi-
fied carbon monoxide as a vasodilator.
What was lacking was a strategic attempt
to elucidate the endothelial-dependent roles
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of endogenously formed carbon monoxide
from those which are endothelium-independ-
ent. In an attempt to clarify this issue, we
recently found that heme can elicit vasodila-
tion of isolated superfused rat gracilis first-
order arterioles denuded of endothelium, in
a manner which is readily reversed by an
inhibitor of heme oxygenase (57). In that
study, carbon monoxide similarly elicited
vasodilation in the preparations denuded of
endothelium. These observations suggest that
a heme oxygenase product, apparently car-
bon monoxide, can produce vasodilation of
these resistance vessels in a manner which is
endothelium-independent. It also suggests
that the vasodilatory actions of heme can be
independent of the generation of endotheli-
um-derived factors.
In sharp contrast, we found that heme
elicited a vasoconstriction in similarly pre-
pared arterioles when the endothelium was
left intact (57). In addition, we found that
the heme-induced vasoconstriction was
readily reversed by the further inclusion of
an inhibitor of heme oxygenase. Further-
more, in similarly prepared vessels in which
the endothelium was left intact, we found
that exogenously applied carbon monoxide
could also elicit a vasoconstrictive response.
These frankly unexpected findings suggested
that a heme oxygenase product, which was
mimicked by carbon monoxide, could also
elicit vasoconstriction by 1) facilitating the
release of a vasoconstrictive agent from the
endothelium or by 2) interfering with the
release of an endothelium-derived relaxing
factor.
Nitric oxide is an endothelium-derived
relaxing factor (29). In addition, nitric oxide
synthase-mediated formation of nitric oxide
has been repeatedly shown to be inhibited by
carbon monoxide (7,49-52). If the observed
endothelium-dependent HLL-induced vaso-
constriction of the gracilis arteriole prepara-
tions were a consequence of inhibition of
nitric oxide synthase activity by endog-
enously formed carbon monoxide, it would
seem reasonable that the blockade of nitric
oxide formation should allow the vasodila-
tory influences of heme-derived carbon mon-
oxide to predominate.
In vessels with intact endothelium and in
which L-NAME is present to maximally in-
hibit nitric oxide synthesis, we find that heme
does elicit vasodilation in a manner which is
reversed by inhibitors of heme oxygenase
(12,53,57). Blockade of nitric oxide synthases
similarly allows the vasodilatory effects of
carbon monoxide to be displayed even when
the endothelium is present (12,53,57). Ac-
cordingly, the simplest explanation is that
heme-derived carbon monoxide, specifical-
ly that formed in smooth muscle, may serve
to promote vasodilation by a local action.
Simultaneously these vasodilatory actions
may be buffered by the consequent with-
drawal of the vasodilatory influences of en-
dothelium-derived nitric oxide.
While such observations are consistent
with the well-documented biochemical ac-
tions of carbon monoxide to block nitric
oxide synthase, they are admittedly in sharp
contrast to the recent dogma which high-
lights the vasodilatory actions of carbon mon-
oxide. Coceani et al. (54) have reported that
vasodilation can be elicited by heme sub-
strate in intact lamb ductus arteriosus ves-
sels. Such findings may seem in contrast to
our recent findings, but they have carefully
documented that heme oxygenase is local-
ized in the smooth muscle domain of their
ductus vessels, but not present in the endo-
thelium.
Given the widely accepted importance of
the nitric oxide system for multiple biologi-
cal processes (29), the possibility of a carbon
monoxide/nitric oxide interaction should be
explored to determine its hemodynamic func-
tional significance. Consideration of this
potential interaction is crucial, since igno-
rance of this feature might seriously con-
found the interpretations of key experiments
in this newly emerging area of endogenous
carbon monoxide research.
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Vasodilatory influences of endogenous
carbon monoxide
While we recently suggested that carbon
monoxide may promote vasoconstriction by
interfering with the vasodilatory influences
of the nitric oxide system, that suggestion
was certainly not intended to overlook the
vasodilatory influences of endogenously
formed carbon monoxide. Given the appar-
ent effects of carbon monoxide attenuating
the vasodilatory influences of the nitric ox-
ide vasodilatory system, the vasodilatory ef-
fects of heme can be optimized by using
preparations in which the nitric oxide system
is inhibited.
In isolated superfused rat gracilis first-
order arterioles with intact endothelium, in
an environment containing L-NAME to maxi-
mally inhibit nitric oxide synthase, heme
does promote vasodilation in a manner which
is readily reversed by inhibitors of heme
oxygenase (53). This suggests the heme-
induced vasodilatory response arises from
the generation of a heme oxygenase product.
These heme-induced vasodilatory effects are
not prevented by an iron chelator or mim-
icked by biliverdin. However, carbon mon-
oxide does mimic this heme-induced dila-
tion of similar preparations. This is the evi-
dence that the vasodilatory heme oxygenase
product is most likely to be carbon monox-
ide.
In similarly prepared resistance vessels,
in which the nitric oxide system has been
maximally inhibited, inhibitors of heme oxy-
genase alone produce a striking vasocon-
striction (12). This vasoconstrictive effect
can be both prevented and reversed by car-
bon monoxide, but cannot be prevented by a
nitric oxide donor. These findings suggest
that the basal production of carbon monox-
ide may exert a substantial vasodilatory in-
fluence on these resistance vessels.
Concerns have recently surfaced over
potential interactions between metallopor-
phyrins and soluble guanylate cyclase (36,
37). However, the arteriolar constriction pro-
duced by chromium mesoporphyrin is unaf-
fected by an inhibitor of soluble guanylate
cyclase (12). Furthermore, vasodilatory ac-
tions of exogenously applied carbon monox-
ide or heme also appear to be unaffected by
an inhibitor of soluble guanylate cyclase in
isolated arteriolar preparations (12). Accord-
ingly, it appears that heme, at least in some
conditions, carbon monoxide and metallo-
porphyrins can produce effects which are
unrelated to soluble guanylate cyclase activ-
ity. While the mechanisms underlying acute
carbon monoxide-induced relaxation of vas-
cular smooth muscle have yet to be clarified,
they apparently arise independently from P-
450-, endothelin- or soluble guanylate cy-
clase-related activities (12).
Proposed organization for
endogenously derived carbon
monoxide effects on cardiovascular
functions
An abundance of literature has accumu-
lated describing intricate details of mecha-
nisms which contribute to heme oxygenase
expression. There has also been a virtually
endless trail of proposed biochemical inter-
actions of carbon monoxide and heme me-
tabolites with almost every imaginable mes-
senger system. While such information is
certainly of tremendous importance, there
may have been a tendency for the biochem-
istry to overwhelm the functional effects of
this newly explored system. The identifica-
tion of the primary functions of endogenously
formed carbon monoxide may serve as a
point of orientation in the search to identify
the underlying primary biochemical and
molecular biological mechanisms. By such
an approach, the physiological contributions
of the heme-heme oxygenase-carbon mon-
oxide system may best be appreciated.
The current review has preferentially
emphasized the apparent functional conse-
quences of the heme-heme oxygenase-car-
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bon monoxide system in an attempt to orga-
nize a framework to identify the primary
influences of endogenously formed carbon
monoxide on cardiovascular functions. What
seems to be emerging are multiple mecha-
nisms by which endogenously formed car-
bon monoxide exerts effects on cardiovas-
cular control.
Specifically, heme-derived carbon mon-
oxide generated within vascular smooth
muscle appears to be vasodilatory. This va-
sodilatory influence may be countered by
carbon monoxide-induced withdrawal of the
endothelium-dependent vasodilatory influ-
ence of the nitric oxide system. This sug-
gests that under some conditions carbon
monoxide may have little direct effect on
basal vascular tone. Even so, such condi-
tions could still interfere with the dynamic
influences related to shear force-mediated
changes of the nitric oxide system and con-
sequently amplify the vasoactive actions of
other agents. Such an arrangement means
that carbon monoxide, even the endogenously
formed one, may promote a propensity for
vasospasms. Since carbon monoxide has been
shown to compete with L-arginine for bind-
ing to nitric oxide synthase, then L-arginine
may potentially protect nitric oxide synthase
from the inhibitory actions of carbon mon-
oxide. It should be emphasized that it is not
clear to what extent the nitric oxide and
carbon monoxide systems interact in vivo.
Nonetheless, potential interactions between
the carbon monoxide- and nitric oxide-gen-
erating systems should be seriously consid-
ered, especially when isolated preparations
are involved.
In addition to the proposed endothelium-
dependent and -independent actions of car-
bon monoxide on vascular tone, it appears
that carbon monoxide can affect blood pres-
sure through CNS-mediated influences on
vascular tone and baroreceptor reflex func-
tions. One region in the brain that has been
strongly implicated as participating in these
functions is the NTS. In some cases, the
actions of the CNS may exert a third influ-
ence which tips the balance of the directly
offsetting endothelium-dependent and -in-
dependent actions of carbon monoxide on
the vasculature.
While the search for functional roles for
the heme-heme oxygenase-carbon monox-
ide system remains in its infancy, the ac-
crued evidence strongly suggests that the
heme metabolic system is doing more than
simply generating carbon monoxide as a
waste product. More specifically, the evi-
dence suggests that heme-derived carbon
monoxide may exert effects on blood pres-
sure by influencing both endothelium-de-
pendent and -independent functions in the
vasculature, and these periferal effects may
be further adjusted by carbon monoxide-
induced influences arising through the cen-
tral nervous system.
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